Know Cancer

or
forgot password

Correlation of Fc Gamma RIIIA Receptor Expression and Response to Rituximab and Other Monoclonal Antibodies in Patients With Waldenstrom's Macroglobulinemia


N/A
30 Years
90 Years
Not Enrolling
Both
Waldenstrom's Macroglobulinemia

Thank you

Trial Information

Correlation of Fc Gamma RIIIA Receptor Expression and Response to Rituximab and Other Monoclonal Antibodies in Patients With Waldenstrom's Macroglobulinemia


- A medical data collection survey sheet will be filled out by the patient or doctor with
medical information pertaining to how the patient responded to rituximab and other
monoclonal antibodies for use in this study.

- Blood work will be performed to analyze the blood by molecular technology to find the
kind of Fc gamna RIIIa receptor the patient possess and correlate these findings with
the outcome of treatment with rituximab or other monoclonal antibodies.


Inclusion Criteria:



- Patients treated with rituximab or other monoclonal antibodies for Waldenstrom's
macroglobulinemia

Type of Study:

Interventional

Study Design:

N/A

Principal Investigator

Steven Treon, MD, MA, PhD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Dana-Farber Cancer Institute

Authority:

United States: Institutional Review Board

Study ID:

02-075

NCT ID:

NCT00142155

Start Date:

January 2002

Completion Date:

March 2007

Related Keywords:

  • Waldenstrom's Macroglobulinemia
  • monoclonal antibody
  • Fc gamma RIII receptor expression
  • rituximab
  • Waldenstrom Macroglobulinemia

Name

Location

Dana-Farber Cancer InstituteBoston, Massachusetts  02115